When Otsuka Pharmaceutical Co. Ltd. won US Food and Drug Administration approval for the first digital pill, Abilify MyCite (aripiprazole tablets with sensor), in 2017, it was viewed as an important milestone, as it showed the agency’s willingness to consider digital medicines, in this case one that included a sensor to track compliance. But while the drug was a commercial disappointment, the biopharma industry remains interested in using digital technology to better track how patients use drugs.
An 8 November panel at the 2022 BioFuture conference in New York highlighted some of the ways that digital health technology is enabling new advances both in keeping a closer eye on how drugs are performing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?